Skip to main content
. 2020 Jun 22;9(1):1771925. doi: 10.1080/2162402X.2020.1771925

Figure 1.

Figure 1.

A CD4 neoantigen vaccine improves LRT-mediated survival of mice with CT26 tumors in a CD8+ T cell-dependent manner. (a–c) CT26 tumor growth (a) and survival (b) of BALB/c mice (n = 7–8/group) locally irradiated with 12 Gy or 3 × 6 Gy at a mean volume of 60 mm3. (c) gp70-AH1 tetramer+ CD8+ T cells in blood of treated mice (n = 4–5/group). (d-f) CT26 tumor growth (d) and survival (e) of mice (n = 7–12/group) locally irradiated with 12 Gy at a mean tumor volume of ~70 mm3 and immunized three times with CT26 PME1 or control RNA-LPX. (f) Gp70-AH1 tetramer+ CD8+ T cells in blood of treated mice (n = all mice/group). (g-i) CT26 tumor growth (g) and survival (h) of mice (n = 8–9/group) immunized with CT26 PME1 or control RNA and locally irradiated at a mean tumor volume of 90 mm3. CD8+ T cells were depleted 6 days after LRT, administering the anti-CD8 antibody every 3–4 days over 3 weeks. (i) Gp70-AH1 tetramer+ CD8+ T cells in blood of treated mice (n = 8–9/group). Significance was determined using (b, e, h) Mantel-cox log-rank test and (c, f, i) one-way ANOVA, Tukey’s multiple comparison test. (a, d, g) Tumor growth is displayed on a log2-scale. Ratios depict frequency of mice with complete tumor responses (CR). Mean±SEM. nd = not determined.